Oncology Institute, Inc. (TOI) Net Equity Issued and Repurchased (2022 - 2025)

Oncology Institute (TOI) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $3.9 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.2 million (changed N/A YoY) and the FY2025 annual result came in at $13.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased eased to $3.9 million in Q4 2025, from $7.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $7.0 million in Q3 2025 to a low of -$75000.0 in Q3 2024.
• A 4-year average of $1.3 million and a median of $96000.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased tumbled 676.92% — and 2025, when it soared 110050.0%.
• Tracing TOI's Net Equity Issued and Repurchased over 4 years: stood at $79000.0 in 2022, then soared by 43.04% to $113000.0 in 2023, then tumbled by 166.37% to -$75000.0 in 2024, then jumped by 5285.33% to $3.9 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $3.9 million (Q4 2025), $7.0 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.